BrightSpring Health Services reports news on its home- and community-based healthcare platform for complex populations, with recurring updates on Pharmacy Solutions and Provider Services. Company announcements commonly cover financial results, guidance, service-line performance, and care delivery across pharmacy, home health care, primary care, rehabilitation and behavioral health.
BrightSpring news also includes capital actions and corporate-structure developments, including secondary offerings of common stock, share repurchases, investor presentations, and completed portfolio changes such as the sale of ResCare Community Living. These updates frame the company around its continuing pharmacy and provider health solutions business.
BrightSpring Health Services (NASDAQ: BTSG) announced that its subsidiary, Onco360®, has been selected as the national pharmacy partner for OJEMDA™, a newly FDA-approved treatment for pediatric low-grade glioma (LGG) with BRAF mutations. This partnership with Day One Biopharmaceuticals aims to provide this cutting-edge, once-weekly oral medication to children aged six months and older who have relapsed or refractory LGG. The approval is based on the FIREFLY-1 clinical trial, and ongoing confirmatory trials are required for continued approval. Onco360® offers specialized oncology medications and support services, including financial assistance, clinical counseling, and insurance verification.
BrightSpring Health Services, Inc. reported strong financial results for Q1 2024, with net revenue of $2,577 million, a 27.0% increase from Q1 2023. The company's Adjusted EBITDA was $131 million, up 13.2% year-over-year. BrightSpring appointed Timothy Wicks to the Board of Directors and increased its 2024 revenue and Adjusted EBITDA guidance. The company is optimistic about its outlook for the year, citing growth in both Pharmacy and Provider segments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.